Kairos Pharma Ltd

Kairos Pharma Ltd, a clinical-stage biopharmaceutical company, is navigating the challenges of oncology therapeutics with its lead candidate ENV105, but faces financial instability and uncertainty about its future success.

Kairos Pharma’s stock surged 88.29% after the company announced positive interim results from a Phase 2 trial of its cancer treatment ENV-105.

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company pioneering oncology therapeutics, with a focus on developing innovative treatments for various cancers and addressing drug resistance and immune suppression.

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company pioneering advancements in oncology therapeutics, offering hope to millions affected by cancer.

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company developing innovative oncology therapeutics to reverse the effects of cancer on the immune system, with a robust market capitalization and global reach.